retatrutide fat loss clinical trial results 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 Retatrutide for weight loss: Study

Retatrutide Clinical Trials Retatrutide is currently in phase III clinical trials, which are the final step before potential approval

SGLT2 inhibitors are not usually prescribed during breastfeeding

Patients may experience headache or cold symptoms, such as sore throat, runny nose, and congestion

Cohort entry was defined as the date of the first-ever prescription for one of the drugs of interest (GLP-1RAs, SGLT2 inhibitors, metformin or other second- or third-line glucose-lowering drugs) during the study period, and their respective first exposure was defined as the index event

Thoughtful design turns these controls from obstacles into helpful guides

Diabetes, Obesity and Metabolism , 24(8), 15531564